10th CAR-TCR Summit – A Decade of Engineering a Disease-Free World
It's a pivotal moment for cell therapy. New trials, breakthrough data, major acquisitions and regulatory shifts are transforming the landscape, bringing both new opportunities, and complex challenges.
To help you navigate this evolving field, the 10th CAR-TCR Summit is the only industry-led meeting providing insights across end-to-end development. Covering stages from discovery to commercial, and exploring a variety of cell types for both oncology and autoimmunity to ensure your team can fast-track progression of durable, safe and accessible cell therapies.
Here’s a breakdown of the end-to-end content you can expect:
- 7 cell therapy modalities represented including NK cells, macrophages, gamma delta T-cells, TILs, myeloid cells, giving you a holistic view of the current therapeutic landscape
- 3 brand-new clinical data presentations covering in vivo therapies, solid tumors, and non-oncology indications, delivering actionable end-to-end clinical intelligence
- 20% leading pharma speaker faculty offering visibility into what the likes of BMS, AstraZeneca, Johnson & Johnson, Novartis, Eli Lilly (and more), are prioritizing and how they’re shaping partnership models
- 70% brand-new speakers bringing fresh thinking and original perspectives on durability, efficacy, manufacturing, quality control, and more
All approaches, all stages of development, all pipeline functions, and content on both oncology and autoimmune indications. That’s what you’ll gain from this extensive, research-led, cell therapy forum.
View the full agenda here: https://ter.li/npu21g
